2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1
2011
MicroRNA Expression Characterizes Oligometastasis(es)
Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR. MicroRNA Expression Characterizes Oligometastasis(es). PLOS ONE 2011, 6: e28650. PMID: 22174856, PMCID: PMC3236765, DOI: 10.1371/journal.pone.0028650.Peer-Reviewed Original ResearchConceptsOligometastatic patientsMetastasis-directed treatmentMetastasis-directed therapyHigh-dose radiotherapyPredictors of progressionMicroRNA-200 (miR-200) familyPolymetastatic progressionMetastatic diseasePatient selectionLocal treatmentCancer stagingMetastatic outcomeXenograft modelMicroRNA classifierPatientsPolymetastasesTumor samplesOligometastasesCell linesTreatmentProgressionBiological basisRadiotherapyExpressionTherapy